Eli Lilly to unveil new obesity‑treatment data at ObesityWeek 2026
+1 new source since this summary was written
Eli Lilly will present Phase 2 and Phase 3 results for its obesity pipeline at ObesityWeek 2026 in Washington, D.C. The EloraTZP combo achieved an average 54.1‑lb (23.3%) weight loss and a 2.9‑point A1C drop after 48 weeks in participants with obesity or overweight and type 2 diabetes. Retatrutide cut obstructive sleep‑apnea events by up to 60.6% and lowered knee‑osteoarthritis pain by up to 73.1% in its Phase 3 TRIUMPH trials. Real‑world surveys showed Foundayo was rated simple to use and eloralintide reduced food cravings and alcohol intake.
Why it matters
The data suggest Lilly’s investigational drugs could expand treatment options for obesity‑related conditions, potentially driving future sales growth if regulatory approval follows. Investors should watch for any FDA filing updates or commercial launch plans that may affect Lilly’s revenue outlook.
Key facts
- 1EloraTZP produced an average weight loss of 54.1 lb (23.3%) at 48 weeks from a baseline of 232.4 lb in adults with obesity or overweight and type 2 diabetes. prnewswire.com
- 2EloraTZP lowered A1C by an average of 2.9 % and 77 % of participants reached normal blood‑sugar levels. prnewswire.com
- 3Retatrutide reduced the apnea‑hypopnea index by an average of 36.1 events per hour (60.6 %) at 80 weeks in the TRIUMPH‑1 trial. prnewswire.com
- 4Retatrutide cut knee‑osteoarthritis pain by an average of 4.3 points (73.1 %) at 80 weeks in the TRIUMPH‑1 trial. prnewswire.com
- 5Foundayo was reported as simple and convenient by 96‑98 % of real‑world survey participants. prnewswire.com
- 6Eloralintide exit interviews showed 74 % of participants reported fewer food cravings and 41 % reported reduced alcohol consumption. prnewswire.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.